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Background: The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly 
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial fibrillation (AF). 
Direct comparisons between NOACs in trials are lacking, leaving an important clinical 
decision-making gap. We aimed to perform a systematic review and meta-analysis to summarize the 
evidence of observational studies for direct comparative effectiveness and safety amongst NOACs in 
patients with AF. 
 
Methods: Conference proceedings and electronic databases including MEDLINE, CINAHL, 
EMBASE and PUBMED were systematically searched. We included observational studies directly 
comparing individual NOACs in patients with nonvalvular AF who were aged ≥18 years for stroke 
prevention. Primary outcome included effectiveness outcome (stroke or systemic embolism) and 
safety outcome (major bleeding). Data were extracted in duplicated by two reviewers independently. 
A random-effects meta-analysis was conducted to synthesize the data from included observational 
studies. We used the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) to rate the overall quality of evidence for each outcome. 
 
Results: Fifteen studies were included for qualitative synthesis, twelve studies for meta-analyses. It 
was found that rivaroxaban and dabigatran were similar with regard to risk of stroke or systemic 
embolism (Hazard ratio [HR] = 1.00, 95% CI: 0.91 - 1.10; evidence quality: low), but rivaroxaban 
was associated with higher risk of major bleeding (HR = 1.39, 95% CI: 1.28 - 1.50; evidence quality: 
moderate). Compared with apixaban, a significantly higher risk of major bleeding was observed with 
rivaroxaban (HR = 1.71, 95% CI: 1.51 - 1.94; evidence quality: low). Apixaban was associated with 
lower risk of major bleeding, in comparison with dabigatran (HR = 0.80, 95% CI: 0.68 - 0.95; 
evidence quality: low). No differences in risk of stroke or systemic embolism was observed between 
rivaroxaban vs. apixaban, and apixaban vs. dabigatran. 
 
Conclusions: In this study, apixaban was found to have the most favorable safety profile amongst the 
three NOACs. No significant difference was observed in risk of stroke or systemic embolism between 
the NOACs. Such findings may provide some decision-making support for physicians regarding their 
choices amongst NOACs in patients with AF.  
 
Registration: PROSPERO (identifier: CRD42016052908) 
 







Atrial fibrillation (AF) is a highly prevalent, age-related cardiac arrhythmia and independently 
increases the risk of stroke by five fold [1,2]. The use of antithrombotic prophylaxis remains the 
mainstay to prevent stroke in patients with nonvalvular AF [3,4]. The non-vitamin K antagonist oral 
anticoagulants (NOACs) have been increasingly prescribed in clinical practice, due to their 
advantages over warfarin such as the decreased need for monitoring, fewer food and drug interactions, 
and more predictable pharmacodynamic effect [5-7].  
 
The efficacy and safety of NOACs compared with warfarin have been presented in respective 
multicenter Phase III randomized controlled trials (RCTs) [8-11]. However, no head-to-head 
comparison between NOACs is available from RCTs; therefore there is a lack of direct clinical 
outcome evidence to inform physicians and patients on the choice amongst NOACs. Some studies 
employed the RCT data to conduct indirect comparison analyses for relative effect estimates between 
NOACs by using the common comparator arm (warfarin) in all the trials [12-18]. Nevertheless, the 
utility and credibility of their results are limited given the difference in populations, outcomes, study 
methodology and designs, and time in therapeutic range in warfarin groups between the respective 
RCTs [19,20]. Besides, whether and how NOACs in real-world circumstances would show different 
effectiveness-safety profiles from those in the ideal RCT settings, and whether similar comparative 
effectiveness-safety profiles would be observed amongst NOACs, remains to be further explored. 
Observational studies provide a platform for direct comparative evaluation amongst NOACs in 
heterogeneous populations in real-world clinical practice, which could supply some evidence to 
physicians to aid in decision-making regarding their choices amongst NOACs.  
 
In this study, we aimed to conduct a systematic review and meta-analysis to summarize the evidence 
of direct comparison from observational studies for the comparative effectiveness and safety between 
NOACs in patients with nonvalvular AF.  
 
Methods  
We conducted this study based on guidance from the Cochrane Handbook of Systematic Reviews and 
reported results according to PRISMA (the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses) recommendations [21,22]. The study protocol was registered in PROSPERO 
(Prospective Register of Ongoing Systematic Reviews; identifier: CRD42016052908). 
 
Search strategy 
We searched the following electronic databases to identify eligible observational studies: MEDLINE, 
CINAHL and EMBASE from Jan 1st, 2009 to November 30th, 2016, because the first NOAC 
(dabigatran) in AF was reported for licensing in 2009 [10]. We also updated the PUBMED search 
from November 2016 up to August 3rd, 2017. We used descriptors including synonyms for 
observational studies, NOACs, stroke or bleeding, and atrial fibrillation in the search (detailed terms 
for search were presented in Supplemental Table 1). Reference lists of included studies and other 
review or editorial articles were also searched for relevant reports. No language restriction was used. 
Three conference proceedings were searched for unpublished and ongoing studies: American College 
of Cardiology (2009 - 2016), European Society of Cardiology (2009 - 2016), and International 




Study eligibility criteria 
Case-control and cohort studies directly comparing individual NOACs in patients with nonvalvular 
AF who were aged ≥18 years for stroke prevention were eligible for inclusion. We focused on factor 
Xa inhibitors (rivaroxaban, edoxaban, and apixaban) and the direct thrombin inhibitor (dabigatran). 
Therefore the comparisons amongst NOACs included dabigatran vs rivaroxaban, dabigatran vs 
apixaban, dabigatran vs edoxaban, rivaroxaban vs apixaban, rivaroxaban vs edoxaban, and apixaban 
vs edoxaban.  
 
If data from the same participants were published in multiple reports or at different time points, we 
chose the study with the largest sample size and longest follow-up. We excluded studies if their 
objectives were not comparative effectiveness or safety profiles of NOACs, or if they could not 
provide data on comparative effectiveness or safety amongst NOACs in patients with AF. Moreover, 
some studies may compare one NOAC (e.g., dabigatran) with a combination of the other NOACs (e.g., 
rivaroxaban and apixaban). These studies were not included if no data on direct comparison (e.g., 
dabigatran vs rivaroxaban, or dabigatran vs apixaban) could be isolated or extracted. Furthermore, we 
excluded studies comparing NOACs in patients for cardioversion or ablation of AF, because of their 
short-term treatment duration and follow-up.  
 
Outcomes  
In this study, the primary outcomes included the effectiveness outcome (a composite of stroke or 
systemic embolism) and the safety outcome (a composite of major bleeding). Given that the included 
studies may define primary outcomes differently, we adopted the definitions from the included 
individual studies and presented their definitions in Table 1. Our secondary outcomes were 
myocardial infarction (MI) and all-cause mortality.  
 
Data extraction and individual study quality assessment  
Two reviewers (G.L. and Y.C.) independently screened and chose eligible studies for inclusion. We 
used the Kappa statistic to quantify the agreement between the two reviewers [23]. Disagreement was 
addressed by discussion between the two reviewers, with a third arbiter available if no consensus 
could be reached. The two reviewers extracted data independently including information on study 
design, patient characteristics, anticoagulant information, outcome assessment, follow-up period, and 
comparative treatment effect estimates.  
 
The Cochrane Collaboration ROBINS-I (Risk of Bias In Non-randomized Studies- of Interventions) 
evaluation tool was used to assess the individual observational study quality [24]. Each study was 
rated as either low, moderate, serious, or critical risk of bias, according to the domains of confounding, 
participant selection, intervention classification, departure from intended intervention, missing data, 
outcome measures, and selective reporting.  
 
Statistical analyses  
We performed a random-effects meta-analysis to synthesize the data by pooling the results of the 
cohort and case-control studies, respectively. We used the adjusted hazard ratios (HRs) for cohort 
studies and odds ratios (ORs) for case-control studies for meta-analyses. Treatment effect estimates 
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were reported with pooled HRs and ORs for cohort studies and case-control studies respectively, each 
with 95% confidence intervals (CIs).  
 
Data on the composite outcomes may not be extracted in some studies, because they may only report 
individual components of the composite outcomes (e.g., they presented results for stroke and systemic 
embolism respectively). For these studies, we only pooled data on stroke for effectiveness outcome, 
and intracranial hemorrhage (ICH) for safety outcome respectively, to avoid duplicate counting of the 
same patients with multiple events in the meta-analyses [25]. Likewise, if multiple doses of a NOAC 
were studied and not combined, we included data only on the highest dose for meta-analysis.  
 
Statistical heterogeneity for included studies was estimated using the I2 statistic, in which a p-value of 
less than 0.1 or an I2 of over 50% indicated significant heterogeneity [21]. To explain heterogeneity in 
primary outcomes, for each comparison amongst NOACs, we conducted the following three 
predefined subgroup analyses by: 1) individual component of composite outcomes (i.e, stroke and 
systemic embolism for effectiveness outcome, and ICH and major gastrointestinal (GI) bleeding for 
safety outcome, respectively), 2) lengths of follow-up (where the median follow-up was used to 
categorize studies as having long- or short follow-up), and 3) different CHADS2 (> 2 vs. ≤ 2) or 
CHA2DS2-VASc (> 3 vs. ≤ 3) scores, and HAS-BLED scores (>2 vs. ≤2). Three sensitivity analyses 
were performed to evaluate the robustness of our main results by: 1) employing a fixed-effects model 
for the meta-analysis, 2) only including low-risk-of-bias studies for analysis, and 3) only pooling data 
on standard doses of NOACs (150 mg b.i.d. for dabigatran, 20 mg o.d. for rivaroxaban, 5 mg b.i.d. for 
apixaban, and 60 mg o.d. for edoxaban).  
 
Assessment of publication bias and quality of a body of evidence across included studies 
We used the Begg’s rank correlation and Egger’s regression tests for primary outcomes to evaluate 
potential publication bias statistically [21]. Funnel plots were also constructed for visual inspection of 
asymmetry. The quality of a body of evidence for this study was rated using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) tool [26]. The quality of 
evidence across included studies could be categorized as very low, low, moderate, or high, based on 
the judgement about the study design, directness of evidence, precision of results, inconsistency of 
results or unexplained heterogeneity, and publication bias [26].  
 
Results 
There were 1,449 records included for screening. After title and abstract screening and duplicate 
removal, we assessed a total of 92 full-text articles for eligibility with an inter-rater Kappa statistic of 
0.80 (95% CI: 0.63 – 0.97) between the assessors. Fifteen studies (nine full texts [20,27-34] and six 
abstracts [35-40]) were eligible to be included for qualitative synthesis, among which there were 
twelve studies (seven full texts [20,28,30-34] and five abstracts [35,37-40]) included for quantitative 
synthesis (Supplemental Figure 1).   
 
Table 1 shows characteristics of the fifteen included studies. Most studies (n = 14) were retrospective 
cohort designs using data from electronic health databases, while only one study was prospective 
cohort research [34]. Thirteen studies focused on NOAC-naive users. All the primary outcome 
measures were identified from ICD-9-CM or ICD-10-CM codes. All fifteen studies investigated 
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comparisons between rivaroxaban and dabigatran (number of patients: 337,661), nine studies 
[27,29,31,32,35,37-40] for rivaroxaban vs. apixaban (number of patients: 128,548), and nine studies 
[27,29,31,32,35,37-40] for apixaban vs. dabigatran (number of patients: 100,724). No studies 
provided data on edoxaban, reflecting its very recent approval. For rivaroxaban vs. dabigatran, the 
included studies were conducted in USA (n =10), China (n = 3), Denmark (n = 1) and Sweden (n = 1). 
Patients had a median age of approximately 72 years, with a median CHADS2 score of 2 and a median 
HAS-BLED score of 2. The follow-up period varied from 110 days to 400 days. Studies with data on 
rivaroxaban vs. apixaban or apixaban vs. dabigatran were performed in USA (n = 8) and Sweden (n = 
1). Patients’ median age was 73 years, median CHADS2 score 2 and median HAS-BLED score 2. 
Only one study provided data on follow-up period of approximately 160 days [31].  
 
Among all the included studies, eight used multivariable survival regression, six propensity score 
method, and one multivariable logistic regression to quantify comparative evaluation amongst 
NOACs, respectively (Table 1). Study quality was evaluated for the nine full texts. Seven studies 
were rated as low-risk-of-bias for effectiveness and safety outcomes [20,28,29,31,32]. There was one 
study [30] rated as moderate-risk-of-bias for stoke or systemic embolism because it did not provide 
information on missing data and it measured transient ischemic attack as a component of effectiveness 
outcome. One study [27] was graded as moderate-risk-of-bias for safety outcomes because of the 
potential selective reporting and no information on missing data.  
 
Rivaroxaban vs. dabigatran  
Figure 1 and Table 2 display results of comparative effectiveness and safety between rivaroxaban and 
dabigatran. Seven studies that provided data on HRs were synthesized, while the other study [29] that 
reported adjusted ORs was not included for meta-analyses. No significant difference in risk of stroke 
or systemic embolism was found between rivaroxaban and dabigatran (HR = 1.00, 95% CI: 0.91 – 
1.10, p = 0.97; Figure 1a). There was marginally significant heterogeneity observed for risk of stroke 
or systemic embolism (I2 = 44%, p-value = 0.1). Compared with dabigatran, rivaroxaban was 
significantly associated with increased risk of major bleeding (HR = 1.39, 95% CI: 1.28 - 1.50, p < 
0.001; Figure 1b). Regarding secondary outcomes, no significant difference was found in risk of MI 
between rivaroxaban and dabigatran (HR = 0.87, 95% CI: 0.72 - 1.05, p = 0.15; Supplemental 
Figure 2), while a higher risk of all-cause death was found with rivaroxaban (HR = 1.28, 95% CI: 
1.14 - 1.43, p < 0.001; Supplemental Figure 3). No statistically significant heterogeneity was found 
for risks of major bleeding, MI and death, with all the I2 of < 50% and p-values of > 0.1.  
 
Likewise, as shown in Table 2, rivaroxaban was non-significantly associated with risk of stroke, but 
significantly associated with increased risk of major GI bleeding, compared with dabigatran. However, 
no significant association was observed for ICH (p = 0.46). Similar results were found in the subgroup 
analysis by HAS-BLED score (p-values > 0.05 for subgroup differences; Table 3). Sensitivity 
analyses also yielded similar results to the main analyses (Table 3).  
 
Rivaroxaban vs. apixaban 
Compared with apixaban, no difference in risk of stroke or systemic embolism was found in 
rivaroxaban (HR = 1.09, 95% CI: 0.96 – 1.24, p = 0.19; Figure 1c and Table 2). However a 
significantly higher risk of major bleeding was observed in rivaroxaban (HR = 1.71, 95% CI: 1.51 – 
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1.94, p < 0.001; Figure 1d and Table 2) with significant heterogeneity found (I2 = 56%, p = 0.04). No 
analyses for effectiveness outcomes or subgroup analyses were conducted due to insufficient studies 
or data available. Similar results were found in sensitivity analyses (Table 3).  
 
Apixaban vs. dabigatran 
In comparison with dabigatran, apixaban was not significantly associated with decreased risk of 
stroke or systemic embolism (HR = 0.94, 95% CI: 0.83 – 1.06, p = 0.32; Figure 1e and Table 2), but 
significantly associated with decreased risk of major bleeding (HR = 0.80, 95% CI: 0.68 – 0.95, p = 
0.01; Figure 1f and Table 2). There was significant heterogeneity found for risk of major bleeding: I2 
= 61%, p = 0·03. No analyses for effectiveness outcomes or subgroup analyses were performed. 
Sensitivity analyses produced similar findings to the main analyses (Table 3).  
 
Assessment of publication bias and quality of a body of evidence 
There was no evidence of publication bias found in the comparison amongst NOACs, with all the 
p-values of > 0·05 for Begg’s and Egger’s tests (Supplemental Figure 4-7). The quality of a body of 
evidence across included studies was rated as low-quality for the effectiveness outcome of 
rivaroxaban vs. dabigatran and for the safety outcomes of rivaroxaban vs. apixaban or apixaban vs. 
dabigatran, due to the non-randomized design and unexplained heterogeneity. The evidence for the 
safety outcome of rivaroxaban vs. dabigatran was graded as moderate-quality because of the 
non-randomized design (Supplemental Table 2).  
 
Discussion  
In this systematic review and meta-analysis, we summarized the evidence from observational studies 
of direct comparative effectiveness and safety amongst NOACs in patients with AF. No significant 
differences in risk of stroke or systemic embolism were found between rivaroxaban vs. dabigatran, 
rivaroxaban vs. apixaban, or apixaban vs. dabigatran. Apixaban was found to have the most favorable 
safety profile amongst the three NOACs.  
 
Apixaban was associated with a lower risk of major bleeding when compared with dabigatran or 
rivaroxaban (Table 2). This finding may provide some decision-making support for physicians 
regarding their choices amongst NOACs, especially when considering the equivalent effect of the 
NOACs on effectiveness outcomes. The evaluated risk of major bleeding and mortality in rivaroxaban 
compared with dabigatran or apixaban may reflect the true difference in safety outcomes between the 
three NOACs. The once-daily dosing of rivaroxaban and twice-daily administration of dabigatran 
might also explain the higher risk of major bleeding in rivaroxaban, given its higher peak in plasma 
concentrations than dabigatran [20]. However, the observed results (no difference in effectiveness, but 
better safety) between rivaroxaban and dabigatran or apixaban may also be partly due to selective 
prescribing. Patients in ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation) were older and frailer, required more orthopedic procedures, and had more baseline 
comorbidities than in RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) or 
ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) [8-10], 
therefore physicians may prefer prescribing rivaroxaban to patients at higher risk of adverse health 
outcomes [30,32]. In addition, once-daily dosing may be preferred for patients on other multiple drugs 
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or with memory problems, to decrease pill burden. Although all the included studies used 
multivariable or propensity score adjustment to estimate the relative effect, the non-randomized 
design could not fully adjust for the effect of selective prescribing or prevent the potential residual 
confounding.  
 
The numbers of studies included for quantitative syntheses of the primary outcomes were relatively 
small (Table 2). Three studies [27,29,36] investigating risk of major bleeding could not be used for 
meta-analyses, because two studies [27,36] did not provide data on the relative effect and the other 
study [29] only reported adjusted ORs (rather than HRs). Nevertheless, they consistently reported 
higher incidence rates of major bleeding during follow-up in rivaroxaban compared with dabigatran or 
apixaban. Likewise, due to insufficient studies available and suboptimal reporting, no analyses of 
using standard NOAC doses or subgroup analyses could be conducted for rivaroxaban vs apixaban or 
apixaban vs dabigatran. Therefore the significant heterogeneity could not be further explored, leading 
to the quality of a body of evidence being low (Supplemental Table 2).  
 
Three studies summarizing the observational evidence of direct comparisons amongst NOACs have 
been published [41-43]. Although our findings were in general agreement with their results, the other 
studies have limitations, either only exploring the comparison between rivaroxaban and dabigatran 
[42,43], or only assessing the safety profiles amongst NOACs [41,43]. There are several studies using 
data from RCTs to indirectly compare efficacy and safety outcome between NOACs [12-18]. Our 
study found similar effectiveness but higher risk of major bleeding in rivaroxaban compared with 
dabigatran, which was not consistent with the indirect comparison studies that showed higher risk of 
stroke or systematic embolism in rivaroxaban but no difference in major bleeding [12,13,15,18]. 
Indirect comparison should be interpreted with caution, given that such comparison is essentially 
observational design across trials and may suffer apparent and latent biases including confounding 
[21,44]. Specifically, the difference in the three RCTs (ROCKET-AF, RE-LY, and ARISTOTLE) 
yielded the indirect comparison questionable and even misleading [19,45], because it remained 
unclear whether and to what extent the difference in risk of outcomes could be attributed to the drug 
alone. Indirect comparison studies can be used to generate hypotheses that are further corroborated 
ideally in direct comparative RCTs [18]. Given that no such RCT is available currently or in the near 
future, findings from real-world studies with direct comparative assessment amongst NOACs may 
assist in decision-making in clinical practice. The large-scale direct design with multivariable or 
propensity score adjustment in the relatively homogeneous patients for each individual study may 
provide more credible evidence than indirect comparison, although an observational study is prone to 
biases due to its non-randomization and should be interpreted with caution. Moreover, four included 
studies evaluated the comparison between NOACs and warfarin and reported consistent findings with 
the respective trials [28,30,31,37]. This would also support the validity of the included observational 
studies and our current review. However, further large-scale, well-designed and transparently-reported 
observational studies or eventually head-to-head clinical trials are needed to update the evidence and 
inform decision-making, because of insufficient studies or data available in our study including 
limited evidence for subgroup evaluations and for risks of MI and death. 
 
Strengths and limitations  
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This study is the first systematic review to summarize evidence from observational studies for direct 
comparison amongst NOACs, to our knowledge. An exhaustive and comprehensive search was 
conducted to obtain all relevant and most-updated studies. Study processes including screening, data 
extraction and analyses were performed in duplicate with a good level of agreement. Results from 
sensitivity analyses supported the robustness of findings from the main analyses.  
 
Some limitations exist in our study. First, the non-randomized comparisons in observational studies 
may suffer from biases, which could impair the findings and thus weaken the strength of evidence. 
Secondly, due to limited studies or data, we could not further evaluate the comparative outcomes of 
interest amongst all NOACs, especially with no data on edoxaban available. Similarly, no analyses 
could be performed in subgroup populations including patients with or without renal dysfunction, 
with different sex, at low or high risk of stroke and/or major bleeding, with high or low drug 
adherence, with or without concomitant over-the-counter antiplatelets, and at different ages. Thirdly, 
the statistical methods used in the included studies including multivariable regression and propensity 
score methods were performed to estimate different relative treatment effects. For instance, the 
propensity score matching was used to estimate effects in the patients who received NOACs; the 
propensity score covariate adjustment was used for conditional effects within levels of the propensity 
scores; and the propensity score inverse probability of treatment weighting and the multivariable 
regression were used to estimate effects in all the patients with AF who were eligible for a NOAC [46]. 
However no analyses could be conducted to compare the different targeted effects due to the small 
number of included studies. Furthermore, all the included studies used ICD-9-CM or ICD-10-CM 
(International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification) codes to 
identify outcomes and no chart reviews were performed to validate outcome measures, which was a 
common limitation of observational analyses based on electronic health databases. For example, it 
was reported that the outcome data (incidences of cardiovascular and bleeding events) identified from 
medical claims after MI were generally lower than from physician adjudication [47]. Therefore 
caution is needed when interpreting such observational studies that depend on the data from electronic 
health databases alone. Additionally, because the follow-up periods were relatively short ranging from 
110 days to 400 days (Table 1), little was known about the long-term comparative effectiveness and 
safety between NOACs in patients with AF in the current study.  
 
Conclusion  
This systematic review and meta-analysis based on observational studies of direct comparative 
effectiveness and safety amongst NOACs in patients with AF found increased risk of major bleeding 
with rivaroxaban compared to dabigatran and apixaban. Apixaban was associated with lower risk of 
major bleeding than dabigatran. No significant difference was observed in risk of stroke or systemic 
embolism amongst the three NOACs. Such findings may provide some decision-making support for 
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Data source Study 
period 

















Center (a cardiology 
outpatient clinic) 
2011 Dec 







Rivaroxaban  Yes  282 (50%) Mean 73 Median 33 
Apixaban  251 (49%) Mean 73 Median 33 
Dabigatran 233 (49%) Mean 72 Median 33 









vs dabigatran  
Rivaroxaban 
(10, 15 and 20 




≥ 1 of study 
drugs 
3,916 (46%) Mean 76 Mean 4.123 
Dabigatran (110 
and 150 mg 
twice daily) 













Rivaroxaban  Unknown; all 
patients 
received a 
NOAC in their 
first 
hospitalization 
due to AF 
(index 
hospitalization) 
37,754 (49%) Mean 72.3 Mean 2.04 
Apixaban  4,138 (51%) Mean 73.6 Mean 2.19 







Cerner Health Facts 
Hospital Database 






Rivaroxaban  Unknown (same 
as above in 
Deitelzweig, 
2016 (a))  
6,635 (48%) Mean 72.1 Mean 2.06 
Apixaban  1,813 (51%) Mean 74.9 Mean 2.35 
Dabigatran 5,753 (45%) Mean 72.4 Mean 2.15 
Graham, 201620 USA Retrospectiv
e cohort 
Medicare databases 2011 Nov 




(20 mg once 
daily) 
Yes 66,651 (47%) N/A (all 
patients 




mg twice daily) 




























Medicare Part D 









(20 mg once 
daily) 




7,322 (50%) Mean 75.6 Mean 3.28 
Li, 2017 China  Prospective 
cohort 
Hospital-based AF 
registry in Queen 
Mary Hospital, 
Hong Kong 




Rivaroxaban  Yes  669 (40%) Mean 73.3 Mean 2.5 
Dabigatran  467 (47%) Mean 71.9 Mean 2.2 








Rivaroxaban  Yes 4,657 (36%) Mean 66.3  Mean 1.6 









Rivaroxaban Yes 7,399 (39%) Mean 68.3 Mean 1.7 
Apixaban  7,399 (39%)  Mean 68.4 Mean 1.8 
Apixaban vs 
dabigatran 
Apixaban Yes 4,407 (36%) Mean 67.0 Mean 1.6 





Optum Labs Data 
Warehouse 
 





Rivaroxaban  Yes 15,787 (40%) Median 70 Median 43 





6,565 (46%) Median 73 Median 43 
Apixaban  6,565 (46%) Median 73 Median 43 
Apixaban vs 
dabigatran 
Apixaban Yes 6,542 (46%) Median 73 Median 43 
Dabigatran 6,542 (46%) Median 73 Median 43 
















Rivaroxaban  Yes 8,398 Mean 67 N/A 
Apixaban  3,689 Mean 69 
Dabigatran 8,539 Mean 66 










Rivaroxaban  Yes 8,740 N/A  Mean 4.03 
Apixaban  3,762 Mean 4.23 
Dabigatran 2,677 Mean 4.03 














Rivaroxaban  Yes  7,667 N/A N/A 
Apixaban  2,028 Mean 75.5 
Dabigatran 5,644 N/A 
Deitelzweig, USA Retrospectiv PharMetrics Plus 2012 Jan - Dabigatran vs Rivaroxaban  Yes  6,167 Mean 63.4 Mean 1.8 
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2015** (b) e cohort data. 
 
2014 Jan Apixaban; 
Rivaroxaban 
vs Apixban 
Apixaban  833 
Dabigatran 2,150 
Lai, 201434 China Retrospectiv
e cohort 














56 (43%) Mean 77.1 Mean 3.1 












Rivaroxaban  Yes  6,407 N/A N/A 
Apixaban  2,038 
Dabigatran 2,440 
* This study was presented by study (a) and (b) because it reported separate findings for the two databases and no combined data could be extracted. 
** These two studies were attached with (a) and (b) to avoid confusion because they were from the same first author and published in the same year 
1 Outcomes were identified from ICD-9-CM or ICD-10-CM codes 
2 Modified HAS-BLED score ranged from 0 to 8 because labile international normalized ratio was not applicable to NOAC users  
3 Data were for CHA2DS2-VASc score;  
4 Data were for Charlson comorbidity index;  
5 Data were for aspirin use only;  
6 Data were for antiplatelet or NSAID use.  
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t use: % 
Effectiveness 
endpoint definition 




N/A N/A 10% 29% N/A Major bleeding defined according to the 
ISTH (International Society of 
Thrombosis and Hemostasis) criteria 
Median 432 days Multivariable 
Cox survival 
regression 
12% 40% Median 348 days 
10% 36% Median 367 days 
Chan, 201628 Mean 3.11  N/A 22% 41% Hospital discharge 
diagnoses for 
ischemic stroke and 
systemic embolism 
Major bleeding required hospitalization,  
including ICH, GI bleeding and other 
critical site bleeding 
N/A Multivariable 
Cox survival 
regression  Mean 3.12 22% 45% 
Deitelzweig, 
2016 (a) 29 
Mean 2.35 Mean 2.094 N/A N/A N/A All major bleeding resulted in a hospital 
readmission within one month of the 
index hospitalization including ICH, GI 




Mean 2.56 Mean 2.354 
Mean 2.33 Mean 2.124 
Deitelzweig, 
2016 (b) 29 
Mean 2.31 Mean 2.394 N/A N/A N/A Major bleeding (same as above in 




Mean 2.50 Mean 2.714 
Mean 2.37 Mean 2.474 
Graham, 
201620 
Median 2 N/A 11% 15% Thromboembolic 
stroke  
ICH; Major extracranial bleeding defined 
as a fatal bleeding event, a hospitalized 
bleeding requiring transfusion, or 
hospitalization with hemorrhage into an 
extracranial critical site 





Median 2 13% 13% Mean 108 days 
Gorst-Rasmus Mean 2.3 N/A 1.5% 44.0%5 Ischemic stroke or Major bleeding including ICH, GI Median 1.08 years Propensity score 
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sen, 201630 Mean 1.9 N/A 1.1% 36.1%5 systemic embolism or 
transient ischemic 
attack  





N/A N/A 28.6% 6.1% Inpatient, emergency 
room, or outpatient 
claim for ischemic 
stroke, systemic 
embolism, transient 
ischemic attack, or 
pulmonary embolism  
Major bleeding including ICH, 
hemoperitoneum, and inpatient or 
emergency room stays for GI, hematuria, 
or not otherwise specified hemorrhage  





N/A  N/A 26.3% 7.1% Mean 385 days 
Li, 2017 Mean 2.0 N/A 0.4% N/A Ischemic stroke that 
led to hospital 
admission 
ICH that led to hospital admission Mean 651 days Multivariable 
Cox survival 
regression 
Mean 2.0 N/A 0.9% N/A 
Lip, 201631 Mean 1.9 Mean 1.6 7.2% N/A N/A Major bleeding defined as bleeding 
requiring hospitalisation during the period 
of drug use or within 30 days after the 
last days of supply of the treatment 
prescription. Using hospital claims 
Mean 173 days Propensity score 
method 
(matching)  
Mean 2.0 Mean 1.6 7.2% Mean 177 days 
Mean 2.1 Mean 1.7 7.9% Mean 182 days 
Mean 2.2  Mean 1.8 8.5% Mean 148 days 
Mean 2.0  Mean 1.6 6.6% Mean 146 days  
Mean 2.0 Mean 1.6 7.4% Mean 179 days 
Noseworthy, 
201632 
Median 2 Median 2 13.3% 10.8%6 Inpatient admission 
for stroke (ischemic 
and hemorrhagic 
stroke) and systemic 
embolism 
Inpatient admission for major bleeding 
including ICH, GI bleeding and major 






Median 2 Median 2 13.7% 11.1%6  
Median 2 Median 2 19.0% 11.7%6  
Median 2 Median 2 19.1% 12.3%6  
Median 2 Median 2 18.8% 12.2%6  






N/A N/A N/A N/A Effectiveness 
outcome defined as  
a composite of 
thromboembolic event 
or stroke 
All Major bleeding required 
hospitalization  





Amin, 2015 N/A N/A N/A N/A N/A Major bleeding events identified by the 
Cunningham algorithm plus additional 













N/A N/A N/A N/A N/A Major bleeding not specified N/A Multivariable 
Cox survival 
regression 
Lai, 201434 N/A N/A N/A N/A N/A Major bleeding including cerebral, 
respiratory, gastrointestinal and urinary 
hemorrhage 
Median 136 days Multivariable 
Cox survival 
regression 
Median 177 days 













Table 2. Results of comparative effectiveness and safety amongst NOACs in patients with AF 
 
Outcome Rivaroxaban vs Dabigatran Rivaroxaban vs Apixaban Apixaban vs Dabigatran 
Number of 
studies/patients 








Pooled HR (95% CI), 
p-value 
Stroke or SE 7/198,445 
 
1.00 (0.91 – 1.10), 
0.97 
2/25,217 1.09 (0.96 – 1.24), 
0.192 
2/25,312 0.94 (0.83 – 1.06), 
0.322 
  Stroke 4/164,722 1.02 (0.89 – 1.16), 
0.753 
1/13,130 -1 1/13,084 -1 
  SE 1/13,121 -1 0/0 -1 0/0 -1 
Major bleeding 7/206,623 
 




1.71 (1.51 – 1.94), < 
0·001 
6/43,470 0.80 (0.68 – 0.95), 
0·01 
  ICH 4/173,423 
 
1.19 (0.75 – 1.88), 
0.46 
1/13,130 -1 1/13,084 -1 
  Major GI bleeding 3/141,849 
 
1.26 (1.18 – 1.36), < 
0·001 
0/0 -1 0/0 -1 
Myocardial infarction 2/128,7282 0.87 (0.72 – 1.05), 
0.15 
0/0 -1 0/0 -1 
All-cause death 4/148,798 
 
1.28 (1.14 – 1.43), 
<0.001 
0/0 -1 0/0 -1 
1 No meta-analysis conducted due to insufficient studies or data available; 
2 Fixed-effects model was used due to only two studies included for analysis; 








Table 3. Results of subgroup and sensitivity analyses for comparison between NOACs 
 
Analysis Stroke or SE* Major bleeding 
Rivaroxaban vs Dabigatran Rivaroxaban vs Dabigatran Rivaroxaban vs Apixaban Apixaban vs Dabigatran 
Subgroup analysis1 
HAS-BLED score     
≤ 2 0.78 (0.60 – 1.02), 0·0522 1.41 (1.13 – 1.76), 0.0022 -3 -3 
> 2 1.01 (0.80 – 1.27), 0·952 1.35 (1.11 – 1.63), 0.0012 -3 -3 
Sensitivity analysis 
 Employing fixed-effects 
model 
1.03 (0.97 – 1.08), 0.38 1.40 (1.31 – 1.49), < 0.001 1.65 (1.52 – 1.79), < 0.001 0.84 (0.76 – 0.92), 
<0.001 
 Only including 
low-risk-of-bias studies  
1.00 (0.90 – 1.11), 0.95 1.35 (1.24 – 1.46), < 0.001 2.11 (1.70 – 2.63), < 0.001 0.69 (0.48 – 0.98), 0.039 
 Using data on standard doses 
of NOACs 
0.96 (0.80 – 1.15), 0.63 1.45 (1.30 – 1.61), < 0.001 -3 -3 
* No syntheses conducted for stroke or SE regarding Rivaroxaban vs Apixaban or Apixaban vs Dabigatran due to only 2 studies included and no data available for 
subgroup analyses  
1 No subgroup analyses performed by length of follow-up, CHADS2 (> 2 vs. ≤ 2) score or CHA2DS2-VASc (> 3 vs. ≤ 3) score because of insufficient studies or data 
available; 
2 Fixed-effects model was used due to only two studies included for analysis; 























Supplemental Table 1. Ovid search terms modified for MEDLINE, EMBASE and CINAHL 
(from Jan 1st, 2009 to Nov 30th, 2016) 
 
Search steps Search terms 
1 atrial fibrillation.mp. or heart atrium fibrillation/ [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
2 atrial flutter.mp. or heart atrium flutter/ 
3 1 or 2 
4 (dabigatran or BIBR1048 or BIBR-1048 or "BIBR 1048").mp. 
5 (rivaroxaban or "BAY 59 7939" or "BAY 59-7939" or "BAY 597939" or 
BAY59-7939 or BAY597939).mp. 
6 (apixaban or BMS-562247 or BMS562247 or "BMS 562247").mp. 
7 (edoxaban or DU-176b or DU176b or "DU 176b").mp. 
8 ("non-vitamin K antagonis$" or "non-vitamin K").tw. 
9 4 or 5 or 6 or 7 or 8 
10 ("observational study" or "observational").mp. 
11 exp cohort study 
12 cohort.mp. 
13 exp case-control study or case-control.mp. 
14 10 or 11 or 12 or 13 















































Supplemental Figure 1. Study flow diagram showing the study selection process 
   
Additional records identified 
through reference lists and 
conference proceedings 
(n = 52) 
Records identified through 
searching MEDLINE, 
EMBASE and CINAHL 
(n =1,292) 
Full-text articles excluded (n = 77): 
➢ Not patients with AF (n = 8) 
➢ No data for head-to-head 
comparison between NOACs (n = 
33) 
➢ Objective not focused on safety 
and/or effectiveness, or no data on 
safety and/or effectiveness (n = 19) 
➢ Duplicates (n = 7)  
➢ Only in patients for cardioversion 
or ablation of AF (n = 7) 
➢ Other reasons (n = 3) 
Studies included in 
meta-analysis (including 7 
full texts and 5 abstracts) 
(n = 12) 
Records after duplicates removed 
(n = 1,277) 
Studies included in 
qualitative synthesis 
(including 9 full texts and 6 
abstracts) 
(n = 15) 
(n = 12) 
Records excluded 
after title and 
abstract screening 
(n = 1,085) 
Full-text articles assessed 
for eligibility 































from updated search 
on PudMed 





Supplemental Figure 2. Relationship between rivaroxaban and risk of myocardial 





Supplemental Figure 3. Relationship between rivaroxaban and risk of all-cause death 





Supplemental Figure 4. Funnel plot for stroke or systemic embolism in the comparison 







Supplemental Figure 5. Funnel plot for major bleeding in the comparison between 





Supplemental Figure 6. Funnel plot for major bleeding in the comparison between 





Supplemental Figure 7. Funnel plot for major bleeding in the comparison between 
apixaban and dabigatran   
38 
 
Supplemental Table 2. Summary of findings for direct comparative effectiveness and 
safety between NOACs in patients with atrial fibrillation 
 
Patient or population: Patients with nonvalvular atrial fibrillation (AF) 
Settings: Multicenter, multinational data from observational studies 
Intervention: NOAC (rivaroxaban, dabigatran, or apixaban) 
Comparison: another NOAC as the reference  

















Results of rivaroxaban vs dabigatran  
Stroke or systemic 
embolism 
Follow-up: varied 
from 110 to 400 days 
Incident rate 
ranging from 
0.1% to 3.7% per 
100 patient-years 
Incident rate ranging 
from 0.1% to 4.2% per 
100 patient-years 
1.001 








from 110 to 400 days 
Incident rate 
ranging from 
0.03% to 3.1% per 
100 patient-years 
Incident rate ranging 
from 0.05% to 5.2% 
per 100 patient-years 
1.391 






Results of rivaroxaban vs apixaban  





1.2% as reported 
in only one study  
Incident rate: 1.0% as 
reported in only one 
study  
1.091 





Follow-up: only one 
study provided data 
on follow-up period 








per 100 patient-years 
1.711 






Results of apixaban vs dabigatran  




1.2% as reported 
in only one study  
Incident rate: 1.2% as 
reported in only one 
study 
0.941 





Follow-up: only one 
study provided data 
on follow-up period 






approximately 2% per 
100 patient-years 
0.771 









*The basis for the assumed risk (e.g. the median control group risk across studies) is provided. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; PS: propensity score; RCT: randomized controlled trial; NOACs: new oral anticoagulants;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the 
estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Expressed as hazard ratios (HRs)  
2 Due to the unexplained heterogeneity and non-randomized design in the included observational studies  
3 Due to the non-randomized design in the included observational studies  
4 Due to insufficient studies or data  
 
